Clinical Trial Momentum in Cell Therapy: 2026 Landscape Report
Cell therapy clinical development is accelerating across multiple dimensions — more trials, faster enrollment, expanded indications, and increasingly innovative trial designs. This report maps the current clinical landscape, identifies momentum signals, and highlights the technologies showing the strongest pipeline acceleration.
Trial Volume and Phase Distribution
ClinicalTrials.gov now lists over 2,400 active cell therapy studies worldwide, representing a substantial increase from approximately 1,800 at the beginning of 2025. The phase distribution shows healthy pipeline maturation, with the ratio of Phase 2 to Phase 1 trials increasing, indicating that earlier-stage programs are successfully advancing.
Phase 3 cell therapy trials have grown by approximately 35% year-over-year, concentrated in CAR-T for hematologic malignancies, MSC-based therapies for graft-versus-host disease and osteoarthritis, and allogeneic cell products seeking to demonstrate non-inferiority to autologous approaches. The emergence of combined Phase 1/2 and Phase 2/3 adaptive trials reflects both regulatory flexibility and sponsor confidence.
CAR-T Expansion Beyond Hematology
The most significant momentum signal in cell therapy is the expansion of CAR-T and related engineered T-cell approaches into solid tumors and autoimmune disease. While hematologic malignancies remain the primary therapeutic area, an increasing number of trials are targeting solid tumors using next-generation approaches including armored CARs, dual-targeting constructs, and CAR-T cells combined with checkpoint inhibitors.
Perhaps more notably, CAR-T approaches are being explored in autoimmune conditions including lupus, inflammatory bowel disease, and multiple sclerosis. Early clinical data showing deep and durable responses in lupus patients has generated significant excitement and accelerated trial initiation in adjacent autoimmune indications.
Allogeneic and iPSC-Derived Approaches
The allogeneic (off-the-shelf) cell therapy paradigm continues to advance, with multiple companies reporting clinical data from gene-edited donor-derived products. The primary advantages — reduced manufacturing time, lower cost per dose, and immediate availability — are driving both clinical development and investor interest.
IPSC-derived cell therapies represent the next frontier, with several programs now in clinical testing. These products offer the potential for truly standardized, scalable manufacturing from a single characterized cell bank. Key challenges include ensuring complete and consistent differentiation, managing tumorigenicity risk, and demonstrating functional equivalence to primary cell-derived products.
Geographic and Sponsor Trends
The geographic distribution of cell therapy trials is shifting, with China continuing to lead in trial volume and the US maintaining dominance in late-stage and pivotal trials. Japan's conditional approval pathway has attracted multiple cell therapy sponsors, and South Korea's regulatory framework continues to support early clinical development.
Sponsor composition is evolving as well. While academic medical centers historically initiated the majority of cell therapy trials, industry-sponsored trials now represent the majority of new registrations. Large pharma companies are increasingly active through acquisitions, licensing deals, and internal pipeline development — a strong signal of commercial conviction in the cell therapy modality.
Key Takeaways
Over 2,400 active cell therapy trials globally, with Phase 3 trials growing ~35% year-over-year.
CAR-T is expanding beyond hematology into solid tumors and autoimmune disease.
Allogeneic and iPSC-derived cell therapies are advancing through clinical development.
Industry-sponsored trials now outnumber academic-initiated trials — a commercial maturity signal.
Adaptive trial designs (combined Phase 1/2, Phase 2/3) reflect regulatory flexibility and sponsor confidence.
Get Intelligence Like This Weekly
Subscribe to the BioIntel.io Weekly Digest for regulatory signals, technology momentum shifts, and enforcement alerts delivered every Monday.